Daniel O'Day

Gilead is best known for two revolutionary antiviral franchises: its HIV treatments (Biktarvy, Descovy — which together dominate the HIV treatment and prevention market) and its hepatitis C cures (Sovaldi, Harvoni — which actually cured HCV but thereby shrank their own market, the so-called "cure paradox"). O'Day's most consequential strategic decision was the $21 billion acquisition of Immunomedics in 2020, adding Trodelvy (sacituzumab govitecan) — an antibody-drug conjugate approved for metastatic triple-negative breast cancer and urothelial cancer. This acquisition marked Gilead's pivot into oncology, diversifying beyond its antiviral base. Trodelvy is being tested in additional cancer indications. The most exciting near-term catalyst is lenacapavir — a long-acting injectable HIV capsid inhibitor that requires injection only twice per year. Clinical trials showed lenacapavir achieved 100% efficacy in preventing HIV infection when administered as pre-exposure prophylaxis (PrEP), which could be transformational for global HIV prevention, particularly in Sub-Saharan Africa. Key stock drivers include Biktarvy sales trajectory, lenacapavir approval and uptake for PrEP and treatment, Trodelvy clinical trial results and label expansions, HIV competitive landscape (particularly long-acting injectables from ViiV/GSK), oncology pipeline progression, and the overall sustainability of HIV franchise growth versus generic erosion.